Axsome Thera (AXSM) Stock Price, Quote & News

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 332 3241

Fax: 212 320 0245

Website: www.axsome.com

Address:

One World Trade Center, 22nd Floor, New York, United States

jozef56 Aug. 6 at 2:02 PM

$AXSM no much big news expected the next 4 till 8 weeks so investers trying their luck with stocks with more volatility. Axsome probably will mostly swing between 95 and 105 but also with some spikes up a downwards. Sell and buy moments.

1 · Reply

pi22dv7 Aug. 6 at 1:41 PM

$AXSM After a STRONG ER and promising update to the pipeline, stonk gets punished, AXSM never disappoints long term investors. Bull-ish?

0 · Reply

jozef56 Aug. 6 at 12:34 PM

$AXSM i like to see a little net profit within 1 year ...must be doable because decrease of r&d projects ...increase in sales...initial sales launches etc etc

1 · Reply

Vakeshka Aug. 6 at 2:23 AM

$AXSM a new Auvelity review just posted on drugs.com Ano... Taken for 1 to 6 months August 4, 2025 For Major Depressive Disorder "I have never written a medication review. I have tried every other type of medication for depression, and they all made me feel worse or zombie-like. Auvelity started lifting my mood within hours. After about a week, I did experience dissociation, fatigue, and major anxiety. However, I stuck it out because it was the first medication I ever felt major symptom relief from and saw other reviews that they had those bad side effects but stuck it out. Now it has been about a month, and I am the happiest I have ever been. I am motivated, it has helped my ADHD more than stimulants, and I am a way better mom, partner, and friend. I am much less irritable and am happy to wake up every day. I did not believe any medication would help me, but Auvelity has been life-changing and a miracle for me!!"

1 · Reply

Idvst8 Aug. 5 at 6:35 PM

$AXSM - High conviction that these are part of the next Sizeable Buyouts in Bio-land $AXSM, $MDGL, $VKTX I also think Sarepta may do some type of Deal at these Valuations in Fall or Winter. Lastly, Sangamo NEEDS a Deal, and needs Cash badly. Will be interesting what old Sandy comes up with. Quite possibly the Largest destruction of shareholders value to Date, without going fully Tits up . They should get a Deal. Their Pipeline is Deep and Valuable.

1 · Reply

quickaspeter Aug. 5 at 5:21 PM

$AXSM Axsome Therapeutics Inc. Q2 2025 ER Highlights: Robust Revenue Growth and… https://www.google.com/url?rct=j&sa=t&url=https://finance.yahoo.com/news/axsome-therapeutics-inc-axsm-q2-070903637.html&ct=ga&cd=CAEYACoTNzc1MzY3OTM5MjA5MDEzNTY2MTIaYzZjNTUzMjg1ZThkMTEzYTpjb206ZW46Q0E&usg=AOvVaw2463w7hLEL5kUQuTTRLo5q

0 · Reply

ZacksResearch Aug. 5 at 4:58 PM

$AXSM Q2 loss beats expectations — but the real story is revenue 🚀 Auvelity sales fueled a 72% year-over-year revenue jump, powering a much narrower quarterly loss. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2668227/axsm-q2-loss-narrower-than-expected-auvelity-drives-revenues-yy?cid=sm-stocktwits-2-2668227-teaser-6120&ADID=SYND_STOCKTWITS_TWEET_2_2668227_TEASER_6120

0 · Reply

ZacksResearch Aug. 5 at 3:22 PM

$AXSM rallies 25.9% YTD — what’s driving the momentum? 🚀 💊 Q2 revenue surged 72% YoY in Q2, beating estimates thanks to strong Auvelity sales for MDD. 📈 Auvelity sales jumped 84% YoY in Q2, with prescriptions up 56%. Discover what’s fueling this growth story 👉 https://www.zacks.com/stock/news/2668227/axsm-q2-loss-narrower-than-expected-auvelity-drives-revenues-yy?cid=sm-stocktwits-2-2668227-body-6026&ADID=SYND_STOCKTWITS_TWEET_2_2668227_BODY_6026

0 · Reply

BiotechBonesaw Aug. 5 at 2:52 PM

$BTAI has competition from $AXSM $ACAD Otsuka and many other biotechs. Again I hope you all help patients but comparing this to $TNXP - which literally has no near-term competition in the fibromyalgia space - doesn’t seem appropriate. 🤷‍♂️

0 · Reply

Uncle_Baby_Billy Aug. 5 at 2:31 PM

$AXSM Damn…..would hate to see what happens with a downgrade🤔

1 · Reply

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Aug 4, 2025, 2:50 PM EDT - 2 days ago

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 2 days ago

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 1:46 PM EDT - 12 days ago

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Jul 21, 2025, 7:30 AM EDT - 16 days ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Jul 9, 2025, 7:00 AM EDT - 4 weeks ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Jul 7, 2025, 7:00 AM EDT - 4 weeks ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Jun 20, 2025, 7:00 AM EDT - 6 weeks ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Jun 11, 2025, 7:00 AM EDT - 2 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

May 29, 2025, 7:00 AM EDT - 2 months ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 2 months ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 13, 2025, 7:00 AM EDT - 3 months ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 6, 2025, 12:48 PM EDT - 3 months ago

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 5, 2025, 11:44 AM EDT - 3 months ago

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:41 AM EDT - 3 months ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 7:00 AM EDT - 3 months ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 3 months ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Apr 8, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Apr 4, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Apr 1, 2025, 7:18 AM EDT - 4 months ago

Axsome's depression treatment fails to meet main goal of late-stage study

Mar 25, 2025, 7:13 AM EDT - 4 months ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 21, 2025, 11:36 AM EDT - 4 months ago

Axsome: The Alzheimer's Agitation Program For AXS-05

Feb 24, 2025, 1:34 PM EST - 5 months ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Feb 20, 2025, 8:15 AM EST - 5 months ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 18, 2025, 11:12 AM EST - 6 months ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:20 PM EST - 6 months ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

TEVA

Feb 10, 2025, 12:33 PM EST - 6 months ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

TEVA

Jan 31, 2025, 7:00 AM EST - 6 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Jan 30, 2025, 3:55 PM EST - 6 months ago

US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:45 PM EST - 6 months ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Dec 31, 2024, 9:15 AM EST - 7 months ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 8:15 AM EST - 7 months ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Dec 30, 2024, 8:13 AM EST - 7 months ago

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

TSLA

Dec 30, 2024, 7:15 AM EST - 7 months ago

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Dec 30, 2024, 7:00 AM EST - 7 months ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Nov 29, 2024, 10:32 AM EST - 8 months ago

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Nov 27, 2024, 1:23 PM EST - 9 months ago

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Nov 12, 2024, 2:02 PM EST - 9 months ago

Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:17 PM EST - 9 months ago

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Nov 8, 2024, 7:00 AM EST - 9 months ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Oct 29, 2024, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Oct 15, 2024, 7:00 AM EDT - 10 months ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Aug 6, 2024, 3:45 PM EDT - 1 year ago

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 5, 2024, 11:20 AM EDT - 1 year ago

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 23, 2024, 4:06 AM EDT - 1 year ago

Axsome Therapeutics: Lots Of Moving Parts

Jul 22, 2024, 3:06 PM EDT - 1 year ago

Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future

jozef56 Aug. 6 at 2:02 PM

1 · Reply

pi22dv7 Aug. 6 at 1:41 PM

$AXSM After a STRONG ER and promising update to the pipeline, stonk gets punished, AXSM never disappoints long term investors. Bull-ish?

0 · Reply

jozef56 Aug. 6 at 12:34 PM

$AXSM i like to see a little net profit within 1 year ...must be doable because decrease of r&d projects ...increase in sales...initial sales launches etc etc

1 · Reply

Vakeshka Aug. 6 at 2:23 AM

1 · Reply

Idvst8 Aug. 5 at 6:35 PM

1 · Reply

quickaspeter Aug. 5 at 5:21 PM

0 · Reply

ZacksResearch Aug. 5 at 4:58 PM

0 · Reply

ZacksResearch Aug. 5 at 3:22 PM

0 · Reply

BiotechBonesaw Aug. 5 at 2:52 PM

0 · Reply

Uncle_Baby_Billy Aug. 5 at 2:31 PM

$AXSM Damn…..would hate to see what happens with a downgrade🤔

1 · Reply

quickaspeter Aug. 5 at 2:22 PM

$AXSM Alright, alright, alright…now, let’s go! 💥🚀💰

1 · Reply

ChappiesWorld Aug. 5 at 2:20 PM

$AXSM obviously we are in a holding pattern between $100-$108 until the Alzheimer's Agitation filing gets accepted or rejected by the FDA. The issue seems to be, if we get a positive outcome, we might get a 5-10% bump. BUT if its rejected or delayed...who knows how far we drop.

1 · Reply

jeremytowe2000 Aug. 5 at 2:19 PM

$AXSM $TGTX Best wishes to all BIO lovers and longs here. I have ended my BIO sector investment adventure officially. Whatever small investment I had left in BIO, I cleared all yesterday. Again best wishes. While I won't be in BIO, I do wish both these stocks reach to much higher.

9 · Reply

pi22dv7 Aug. 5 at 1:41 PM

$AXSM All these analysts should keep quiet :-), these raises means nothing to AXSM PPS, what’s the point of this?

2 · Reply

Vakeshka Aug. 5 at 1:40 PM

$AXSM RBC raises PT to $189 from $184, keeps Outperform rating.

0 · Reply

Vakeshka Aug. 5 at 12:26 PM

$AXSM "Bank of America has increased its price target for Axsome Therapeutics from $173 to $176, maintaining a Buy rating for the stock. This decision comes in light of the company's strong performance in the second quarter, with revenues outperforming expectations due to solid sales of Auvelity and Sunosi. The bank's analysts believe that the full potential of Auvelity across various indications is not fully recognized in the market..."

0 · Reply

Vakeshka Aug. 5 at 9:46 AM

$AXSM Cerena Chen from Wells Fargo maintained a Buy rating on Axsome Therapeutics, with a price target of $165.00

0 · Reply

Vakeshka Aug. 5 at 9:45 AM

$AXSM "...Axsome Therapeutics Inc (AXSM, Financial) demonstrates significant strengths in its expanding product portfolio and strategic partnerships, which are key drivers of its revenue growth. However, the company faces challenges in managing its financial performance and net losses. Opportunities for growth are abundant in the burgeoning CNS market, but Axsome must also contend with competitive threats and regulatory challenges. By leveraging its strengths and addressing its weaknesses, Axsome can capitalize on opportunities and mitigate threats, positioning itself for long-term success in the CNS therapeutic space... https://www.gurufocus.com/news/3033519/decoding-axsome-therapeutics-inc-axsm-a-strategic-swot-insight?r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

0 · Reply

Mike826_1999 Aug. 5 at 9:37 AM

$AXSM Three key dimensions of how “smart money” is positioned in Axsome and the broader health-care hedge fund universe: 1. Active vs Passive Institutional Ownership of AXSM. 70.1%** of Axsome’s institutional holders are **active managers** (i.e. they pick stocks, rather than just track an index). * Historically, that’s sat between **54%** (low) and **99%** (high) — so Axsome today is in the **lower‐middle** of its active-manager ownership range. 2. Hedge-Fund “Long/Short” & Net-Exposure in Health Care. Long/Short Ratio** (long exposure ÷ short exposure) in health care has been as low as \~1.4x and as high as \~2.6x over the last decade. * Today it’s around **2.2x**, **above** its long-term median (\~2.0x) but off the peak seen in 2021–22. * **Net Exposure** (health-care weight as a % of total net hedge-fund positions) has ranged from \~8% to \~26%. * Currently it sits near **19%**, **above** its long-run median (\~15%), reflecting an overall **overweight** stance in the sector. Continued

1 · Reply

Mike826_1999 Aug. 5 at 9:19 AM

$AXSM According to Morgan Stanley’s August 4, 2025 research note on Axsome Therapeutics, their positive and negative views break down roughly as follows: Positive Highlights Auvelity launch execution Auvelity generated $120 M in 2Q 2025 sales, coming in ~8% above Morgan Stanley’s $115 M estimate (and 8% above consensus) and delivering 24% quarter-over-quarter growth. Broad CNS pipeline momentum “Axsome is progressing multiple programs as part of a broad CNS pipeline,” with near-term catalysts (e.g., Alzheimer’s agitation sNDA, pivotal trials in smoking cessation and fibromyalgia) that could “present upside surprises to the market’s current expectations.” Regulatory progress The sNDA filing for AXS-05 in Alzheimer’s disease agitation is on-track for 3Q 2025, an event Morgan Stanley views as a significant value inflection. Strong cash runway Axsome exited 2Q 2025 with ~$303 M in cash and equivalents, “sufficient to fund operations into cash-flow positivity.” Continued

1 · Reply

RickSanders9 Aug. 5 at 2:17 AM

$AXSM 3 qtr's ago, HT used verbiage indicating active interest in the possibility of an EX-Us partnership. I don't work in the field, but you'd think one analyst would inquire about it, in-place of their lazy, layup question. "Hi, this is Mike/Jlfrom from STwits Investments. Has there been an movement or progess on an international partnership?" Give it some thought, fellas....

3 · Reply

Vakeshka Aug. 5 at 1:29 AM

$AXSM Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on AXSM stock, giving a Buy rating...due to a combination of factors including Axsome Therapeutics’ strong financial performance and growth potential. The company’s second-quarter earnings per share exceeded expectations, driven by better-than-anticipated results from Auvelity and Sunosi. This success has led to an increase in forecasts for Auvelity’s major depressive disorder (MDD) treatment, with expectations of continued prescription growth supported by favorable payer contracting. Additionally, while Symbravo’s initial revenues were modest, this was anticipated due to its recent market entry. The focus on targeted headache centers is expected to enhance its performance over time. Furthermore, Auvelity’s expanding presence in the primary care segment, along with increased payer coverage, positions it well for future growth...

0 · Reply

Market Cap	5.25B
Revenue (ttm)	385.69M
Net Income (ttm)	-287.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.47%
Debt to Equity Ratio	3.41

Volume	531,768
Avg Vol	669,734
Day's Range	N/A - N/A
Shares Out	49.24M
Stochastic %K	54%
Beta	0.51
Analysts	Strong Sell
Price Target	$175.67